A Phase 1 interventional study of metronidazole IV 500 mg in Infection, sponsored by Pfizer. Completed at 1 site in Japan. Open to participants aged 20 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2011-09-28.
Sponsored by Pfizer · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to assess the safety, tolerability and pharmacokinetics of metronidazole following single and multiple intravenous infusion in healthy Japanese adult subjects.
2,096 studies on the registry are indexed under Infections; 364 are open to participants now.
This study's enrollment of 6 is below the median of 113 across 1,304 interventional studies indexed under Infections.
Browse Infections studies →Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: metronidazole IV 500 mg
On Day 1, subjects will receive a single dose of 500 mg metronidazole by intravenous infusion over 20 minutes. On Day 3 to Day 7, subjects will receive multiple doses of 500 mg metronidazole by intravenous infusion over 20 minutes 4 times a day (every 6 hours) for 5 days.
Plasma metronidazole pharmacokinetic parameters for single dose:Cmax
Time frame: Day 1 to Day 3
Plasma metronidazole pharmacokinetic parameters for single dose:AUClast
Time frame: Day 1 to Day 3
Plasma metronidazole pharmacokinetic parameters for single dose:AUC0-6
Time frame: Day 1 to Day 3
Plasma metronidazole pharmacokinetic parameters for single dose:Tmax
Time frame: Day 1 to Day 3
Plasma metronidazole pharmacokinetic parameters for multiple dose:Ctrough
Time frame: prior to Day 3 and Day 6-8 morning dose and 6 hours post morning dose on Day 8
Plasma metronidazole pharmacokinetic parameters for multiple dose:Cmax
Time frame: Day 8 to Day 9
Plasma metronidazole pharmacokinetic parameters for multiple dose:AUC0-6
Time frame: Day 8 to Day 9
Plasma metronidazole pharmacokinetic parameters for multiple dose:Tmax
Time frame: Day 8 to Day 9
Plasma metronidazole pharmacokinetic parameters for multiple dose:CL
Time frame: Day 8 to Day 9
Plasma 1-(2-hydroxyethyl)-2-hydroxymethyl-5-nitroimidazole pharmacokinetic parameters for single dose: Cmax
Time frame: Day 1 to Day 3
Plasma 1-(2-hydroxyethyl)-2-hydroxymethyl-5-nitroimidazole pharmacokinetic parameters for single dose: AUClast
Time frame: Day 1 to Day 3
Plasma 1-(2-hydroxyethyl)-2-hydroxymethyl-5-nitroimidazole pharmacokinetic parameters for single dose: AUC0-6
Time frame: Day 1 to Day 3
Plasma 1-(2-hydroxyethyl)-2-hydroxymethyl-5-nitroimidazole pharmacokinetic parameters for single dose: Tmax
Time frame: Day 1 to Day 3
Plasma 1-(2-hydroxyethyl)-2-hydroxymethyl-5-nitroimidazole pharmacokinetic parameters for multiple dose: Ctrough
Time frame: prior to Day 3 and Day 6-8 morning dose and 6 hours post morning dose on Day 8
Plasma 1-(2-hydroxyethyl)-2-hydroxymethyl-5-nitroimidazole pharmacokinetic parameters for multiple dose: Cmax
Time frame: Day 8 to Day 9
Plasma 1-(2-hydroxyethyl)-2-hydroxymethyl-5-nitroimidazole pharmacokinetic parameters for multiple dose: AUC0-6
Time frame: Day 8 to Day 9
Plasma 1-(2-hydroxyethyl)-2-hydroxymethyl-5-nitroimidazole pharmacokinetic parameters for multiple dose: Tmax
Time frame: Day 8 to Day 9
The record gives a start of Aug 2011, a primary completion of Sep 2011 and a completion of Sep 2011. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Metronidazole